Skip to main content
. 2016 Nov;13(11):2045–2056. doi: 10.1513/AnnalsATS.201606-426FR

Figure 1.

Figure 1.

Proposed algorithm for the initiation of SSc-ILD (systemic sclerosis–associated interstitial lung disease)–targeted therapy. *We consider a clinically significant decline in FVC as greater than 10% and a decline in DlCO (diffusing capacity of the lung for carbon monoxide) as greater than 15%, in the absence of pulmonary hypertension. HRCT = high-resolution computed tomography; PFTs = pulmonary function tests.